AT-5214 is a single isomer of mecamylamine that inhibits α3β4 nicotinic receptors and is a potent nicotine acetylcholine antagonist
Primary hyperhidrosis is associated with a selective increase in sympathetic activity
AT-5214 will inhibit primary hyperhidrosis in all localizations
Rapid and cost effective development path in primary hyperhidrosis. Over 2,900 patients have been treated with AT-5214 for other indications with a well and favorable characterized and favorable safety profile
Currently, Atacama successfully completed is testing of AT-5214 in a Phase 2 clinical trial for palmar hyperhidrosis.
Strong support from KOLs and the key hyperhidrosis patient advocacy group